This article from the Wall Street Journal reports on Celgene's acquisition of Pharmion, which makes treatments for patients with blood cancer. Celgene, a biotech company, will make the purchase for $2.9 billion in cash and stock in an effort "to become a major global player in developing and marketing blood-cancer drugs," according to the article.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.